03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with the...
02:29 , May 18, 2018 |  BC Week In Review  |  Clinical News

CTTQ's tyrosine kinase inhibitor gets Chinese approval for NSCLC

The State Drug Administration (formerly CFDA) approved Focus V anlotinib from Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (Nanjing, China) to treat advanced non-small cell lung cancer. CTTQ has Chinese rights to anlotinib from Advenchen Laboratories...
21:18 , May 11, 2018 |  BC Extra  |  Company News

CTTQ's tyrosine kinase inhibitor gets Chinese approval for NSCLC

The State Drug Administration (formerly CFDA) approved Focus V anlotinib from Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (Nanjing, China) to treat advanced non-small cell lung cancer. CTTQ has Chinese rights to anlotinib from Advenchen Laboratories...
00:57 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Chia Tai Tianqing reports Phase III data for anlotinib in NSCLC

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (Nanjing, China) reported data from the Phase III ALTER0303 trial in 437 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) who progressed after ≥2 lines of therapy...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Clinical News

Anlotinib: Phase II data

Data from 154 evaluable patients with STS in an open-label, Chinese Phase II trial showed that once-daily 12 mg anlotinib for the first 2 weeks of each 3-week cycle led to an objective response rate...